Holen Sie sich die Stockscreener-App
11.32
1.34%
0.155
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Keros Therapeutics Announces Share Repurchase Authorization Program - TipRanks
Keros Therapeutics Announces $5 Million Share Repurchase Authorization - The Manila Times
Keros approves $5M buyback after $20M Takeda milestone; cash runway into H2 2028 - TradingView
Keros Therapeutics announces $5M share repurchase program after Takeda payment - TipRanks
Keros Therapeutics, Inc. announces an Equity Buyback for $5 million worth of its shares. - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Keros Therapeutics (NASDAQ:KROS) Downgraded by Wall Street Zen to "Strong Sell" - MarketBeat
Keros Therapeutics (NASDAQ:KROS): Is Its Pipeline Worth the Risk? - Kalkine Media
Empowered Funds LLC Makes New Investment in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Understanding the Setup: (KROS) and Scalable Risk - news.stocktradersdaily.com
Keros Therapeutics director Bienaime buys $10,270 in shares By Investing.com - Investing.com South Africa
Keros Therapeutics director Bienaime buys $10,270 in shares - Investing.com
Wells Fargo Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report? - Yahoo Finance
Man Group plc Purchases Shares of 155,541 Keros Therapeutics, Inc. $KROS - MarketBeat
BlackRock Inc. Buys Shares of 2,794,217 Keros Therapeutics, Inc. $KROS - MarketBeat
127,885 Shares in Keros Therapeutics, Inc. $KROS Purchased by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
Nantahala Capital Management LLC Takes Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Upgraded to "Hold" at Zacks Research - MarketBeat
Keros Therapeutics director Bienaime buys $10,270 of KROS stock By Investing.com - Investing.com India
Keros Therapeutics director Bienaime buys $10,270 of KROS stock - Investing.com
ADAR1 Capital Management LLC Acquires New Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Pipeline Progress Gains Focus - Kalkine Media
Lorena Raquel Lerner Sells 3,568 Shares of Keros Therapeutics (NASDAQ:KROS) Stock - MarketBeat
Keros (KROS) Today: Moves 4.95% Down to $10.55 in the Latest Session; Market Levels: $10.02 and $11.08 Define the Nearby Reference Levels in the Available RecordPut Support - vinanet.vn
Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan
Keros Therapeutics (NASDAQ: KROS) director schedules 551-share sale - Stock Titan
Keros Therapeutics Secures $20 Million Milestone Payment From Takeda - sekbernews.id
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Keros Therapeutics (KROS) Drops 5.25% to $10.1 — Support at $9.59 in FocusEarnings Miss Risk - vinanet.vn
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity? - Yahoo Finance
Understanding Momentum Shifts in (KROS) - Stock Traders Daily
Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.83, Implies 86% Upside - TradingView
BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20 - marketscreener.com
KROS Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Investment CostsRevenue Warning Signal - vinanet.vn
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen - MarketBeat
Renaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics, Inc. (KROS) Stock Analysis: Unveiling a 90.92% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - qz.com
FY2026 EPS Estimate for Keros Therapeutics Raised by Analyst - MarketBeat
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus - The Globe and Mail
KROS Maintained by Wells Fargo -- Price Target Lowered to $18.00 - GuruFocus
Leerink Partners Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
Keros Therapeutics (NASDAQ:KROS) Price Target Lowered to $23.00 at Leerink Partners - MarketBeat
Keros Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
KEROS THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $23 FROM $30 - Bitget
Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS - MarketBeat
Keros Therapeutics 2026: Revenue $0 EPS ($1.45) — 10-Q Summary - TradingView
Keros Therapeutics Reports Second Quarter 2026 Financial Results - The Manila Times
Keros Therapeutics posts $28.7 million second quarter net loss - Quiver Quantitative
KROS: Reduced net loss and strong cash position support ongoing clinical progress into 2028 - TradingView
Avoiding Lag: Real-Time Signals in (KROS) Movement - Stock Traders Daily
Keros Therapeutics, Inc. (KROS) Free Cash Flow 2025: $106.0M, up 165.1% - Stock Titan
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - qz.com
Keros Therapeutics, Inc. (KROS) Stock Analysis: Navigating a 113.63% Potential Upside in Biotechnology - DirectorsTalk Interviews
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
Keros Therapeutics to Receive $20M Development Milestone Payment From Takeda - Moomoo
Keros Therapeutics Earns Milestone Payment for Elritercept Trial - TipRanks
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):